Search results for " Pharmacology"

showing 10 items of 1328 documents

Improving Docking Performance Using Negative Image-Based Rescoring

2017

Despite the large computational costs of molecular docking, the default scoring functions are often unable to recognize the active hits from the inactive molecules in large-scale virtual screening experiments. Thus, even though a correct binding pose might be sampled during the docking, the active compound or its biologically relevant pose is not necessarily given high enough score to arouse the attention. Various rescoring and post-processing approaches have emerged for improving the docking performance. Here, it is shown that the very early enrichment (number of actives scored higher than 1% of the highest ranked decoys) can be improved on average 2.5-fold or even 8.7-fold by comparing th…

0301 basic medicineComputer scienceEnergy minimizationconsensus scoring03 medical and health sciencesmolekyylilääketiedeta318Pharmacology (medical)benchmarkingdocking rescoringOriginal ResearchPharmacologyVirtual screeningDrug discoverybusiness.industrylcsh:RM1-950Pattern recognitionmolecular dockingnegative image-based rescoring (R-NiB)030104 developmental biologylcsh:Therapeutics. PharmacologyActive compoundDocking (molecular)Target proteinArtificial intelligencebusinessFrontiers in Pharmacology
researchProduct

Characterization of myofibroblasts isolated from the intestine of patients with inflammatory bowel disease

2019

Background: Intestinal fibrosis represents a serious complication of inflammatory bowel diseases (IBD), often necessitating surgical resections. Myofibroblasts are primarily responsible for interstitial matrix accumulation in fibrotic diseases. However intestinal myofibroblasts (IMF) remain inadequately characterized.  The aim was to examine fibroblast markers and fibrosis-associated gene expression in IMF isolated from resected intestine from IBD and control patients. As well as determining the effect of the fibrogenic cytokine TGFβ. Methods: Intestinal resections were obtained (n =35) from consenting patients undergoing elective surgery (2014-16). Primary cultures of IMF were isolated usi…

0301 basic medicineCrohn's diseaseGeneral Immunology and Microbiologybusiness.industrymedicine.medical_treatmentGeneral Medicinemedicine.diseaseInflammatory bowel diseaseGeneral Biochemistry Genetics and Molecular BiologyCTGF03 medical and health sciences030104 developmental biology0302 clinical medicineCytokineInterstitial matrixFibrosismedicineCancer research030211 gastroenterology & hepatologyTumor necrosis factor alphaGeneral Pharmacology Toxicology and PharmaceuticsbusinessTIMP1F1000Research
researchProduct

Recombinant Ganoderma lucidum Immunomodulatory Protein Improves the Treatment for Chemotherapy-Induced Neutropenia

2020

Ganoderma lucidum, also known as LINGZHI, has a long tradition of use in folk medicine of the Far East, which is documented in the oldest Chinese pharmacopoeia, declaring it a superior medicine. LINGZHI-8 (LZ-8) is an immunoregulatory fungal protein isolated from the fruiting body of Ganoderma lucidum. Neutropenia is a condition with an abnormally low levels of neutrophils in the blood, which is caused by numerous medical conditions or medications, such as chemotherapy. The current study demonstrated that recombinant LZ-8 (rLZ-8) from Pichia promoted the differentiation of bone marrow hematopoietic stem cells (HSCs) into granulocytes in a neutropenia mouse model induced by cyclophosphamide.…

0301 basic medicineCyclophosphamidegranulocyte-colony stimulating factorPharmacologyNeutropeniaColony stimulating factor 1 receptor03 medical and health sciences0302 clinical medicinecolony-stimulating factor 1 receptormedicineneutropeniaPharmacology (medical)rLZ-8Original ResearchPharmacologyFungal proteinbusiness.industrylcsh:RM1-950medicine.diseasehematopoietic stem cellsGranulocyte colony-stimulating factorHaematopoiesislcsh:Therapeutics. Pharmacology030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisBone marrowStem cellbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Retract p < 0.005 and propose using JASP, instead

2018

Seeking to address the lack of research reproducibility in science, including psychology and the life sciences, a pragmatic solution has been raised recently:  to use a stricter p < 0.005 standard for statistical significance when claiming evidence of new discoveries. Notwithstanding its potential impact, the proposal has motivated a large mass of authors to dispute it from different philosophical and methodological angles. This article reflects on the original argument and the consequent counterarguments, and concludes with a simpler and better-suited alternative that the authors of the proposal knew about and, perhaps, should have made from their Jeffresian perspective: to use a Bayes …

0301 basic medicineData SharingOpen scienceComputer scienceresearch evidenceGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineArgumentFrequentist inferenceOrder (exchange)practical significanceBayes factorsPrior probabilityreplicabilityp-valueGeneral Pharmacology Toxicology and Pharmaceuticsreproducibilitystatistical significancePotential impactGeneral Immunology and MicrobiologyPerspective (graphical)Bayes factorArticlesGeneral MedicineOpinion ArticleEpistemology030104 developmental biologyp-values030217 neurology & neurosurgeryF1000Research
researchProduct

Identification of novel drug resistance mechanisms by genomic and transcriptomic profiling of glioblastoma cells with mutation-activated EGFR.

2021

Abstract Aims Epidermal growth factor receptor (EGFR) is not only involved in carcinogenesis, but also in chemoresistance. We characterized U87.MGΔEGFR glioblastoma cells with constitutively active EGFR due to deletion at the ligand binding domain in terms of gene expression profiling and chromosomal aberrations. Wild-type U87.MG cells served as control. Materials and methods RNA sequencing and network analyses (Ingenuity Pathway Analysis) were performed to identify novel drug resistance mechanisms related to expression of mutation activated EGFR. Chromosomal aberrations were characterized by multicolor fluorescence in situ hybridization (mFISH) and array comparative genomic hybridization (…

0301 basic medicineDown-RegulationBiologymedicine.disease_cause030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyTranscriptome03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansGene Regulatory NetworksProtein Interaction MapsGeneral Pharmacology Toxicology and PharmaceuticsGeneTranscription factorMetaphaseChromosome AberrationsMutationmedicine.diagnostic_testBrain NeoplasmsGene Expression ProfilingGeneral MedicineGenomicsUp-RegulationGene expression profilingErbB ReceptorsGene Expression Regulation Neoplastic030104 developmental biologyDrug Resistance NeoplasmMutationCancer researchCarcinogenesisGlioblastomaTranscriptomeComparative genomic hybridizationFluorescence in situ hybridizationSignal TransductionLife sciences
researchProduct

Oridonin Targets Multiple Drug-Resistant Tumor Cells as Determined by in Silico and in Vitro Analyses

2018

Drug resistance is one of the main reasons of chemotherapy failure. Therefore, overcoming drug resistance is an invaluable approach to identify novel anticancer drugs that have the potential to bypass or overcome resistance to established drugs and to substantially increase life span of cancer patients for effective chemotherapy. Oridonin is a cytotoxic diterpenoid isolated from Rabdosia rubescens with in vivo anticancer activity. In the present study, we evaluated the cytotoxicity of oridonin toward a panel of drug-resistant cancer cells overexpressing ABCB1, ABCG2, or ΔEGFR or with a knockout deletion of TP53. Interestingly, oridonin revealed lower degree of resistance than the control dr…

0301 basic medicineDrug resistancenatural compound03 medical and health sciences0302 clinical medicineIn vivomedicinePharmacology (medical)DoxorubicinProtein kinase BPI3K/AKT/mTOR pathwayOriginal ResearchPharmacologydrug resistanceChemistrylcsh:RM1-950molecular dockingmolecular dynamics030104 developmental biologylcsh:Therapeutics. PharmacologyDocking (molecular)030220 oncology & carcinogenesisPharmacogenomicsCancer cellCancer researchmicroarraymedicine.drugcluster analysisFrontiers in Pharmacology
researchProduct

Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach

2015

Drug development in Systemic Lupus Erythematosus (SLE) has been hindered by poor translation from successful preclinical experiments to clinical efficacy. This lack of success has been attributed to the high heterogeneity of SLE patients and to the lack of understanding of disease physiopathology. Modelling approaches could be useful for supporting the identification of targets, biomarkers and patient subpopulations with differential response to drugs. However, the use of traditional quantitative models based on differential equations is not justifiable in a sparse data situation. Boolean networks models are less demanding on the required data to be implemented and can provide insights into…

0301 basic medicineDrugSystems biologymedia_common.quotation_subjectPharmaceutical ScienceAntineoplastic AgentsDiseaseBioinformaticsAutoimmune Diseases03 medical and health sciencesmedicineAnimalsCluster AnalysisHumansLupus Erythematosus SystemicComputer Simulationmedia_commonAutoimmune diseaseLupus erythematosusbusiness.industrySystems Biologymedicine.diseaseTreatment Outcome030104 developmental biologyDrug developmentPharmacology ClinicalbusinessBiological networkSystems pharmacologyEuropean Journal of Pharmaceutical Sciences
researchProduct

Overview of key molecular and pharmacological targets for diabetes and associated diseases

2021

Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by c…

0301 basic medicineDrugmedia_common.quotation_subjectDiseaseType 2 diabetesBioinformatics030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyNephropathyDiabetes Complications03 medical and health sciences0302 clinical medicineDiabetes mellitusDrug DiscoveryDiabetes MellitusAnimalsHumansHypoglycemic AgentsMedicineMolecular Targeted TherapyPharmacology & PharmacyGeneral Pharmacology Toxicology and Pharmaceuticsmedia_commonGlycemicbusiness.industry0601 Biochemistry and Cell Biology 1115 Pharmacology and Pharmaceutical SciencesGeneral MedicineMolecular PharmacologyA300medicine.diseaseHuman genetics030104 developmental biologybusinessSignal Transduction
researchProduct

Identification of NF-κB as Determinant of Posttraumatic Stress Disorder and Its Inhibition by the Chinese Herbal Remedy Free and Easy Wanderer

2017

Posttraumatic stress disorder (PTSD) is a mental disorder developing after exposure to traumatic events. Although psychotherapy reveals some therapeutic effectiveness, clinically sustainable cure is still uncertain. Some Chinese herbal formulae are reported to work well clinically against mental diseases in Asian countries, but the safety and their mode of action are still unclear. In this study, we investigated the mechanisms of Chinese remedy free and easy wanderer (FAEW) on PTSD. We used a reverse pharmacology approach combining clinical data to search for mechanisms of PTSD with subsequent in vitro verification and bioinformatics techniques as follows: (1) by analyzing microarray-based …

0301 basic medicineDrugmedicine.medical_specialtypharmacognosyMicroarraymedia_common.quotation_subjectPharmacologyNF-κB03 medical and health scienceschemistry.chemical_compoundIn vivofree and easy wanderermedicinePharmacology (medical)PsychiatryMode of actionOriginal Researchmedia_commonPharmacologyFluoxetineReverse pharmacologybusiness.industryPaeoniflorin030104 developmental biologychemistryinflammationposttraumatic stress disorderAntidepressantbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.

2019

Introduction: The advent of biologic agents has revolutionized therapeutic approaches in systemic juvenile idiopatic arthritis (sJIA) as their introduction has been shown to modify disease course and improve overall outcomes, particularly when initiated early. Few studies have reported the drug retention rate (DRR) of biologic drugs in JIA, and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on sJIA. Objectives: The primary aim of the study was to examine the overall DRR of IL-1 blockers in sJIA patients. Secondary aims of our study were to: (i) explore the influence of biologic line of treatment, adverse events (AEs), type of anti-IL-1 agent and the conc…

0301 basic medicineDrugmedicine.medical_specialtysystemic juvenile idiopathic arthritismedia_common.quotation_subjectArthritisanakinra; canakinumab; drug retention rate; interleukin 1-beta; systemic juvenile idiopathic arthritis; therapycanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInterleukin-1 inhibitors Systemic Juvenile Idiopathic Arthritis Anakinra CanakinumabInternal medicineinterleukin 1-betaMedicinePharmacology (medical)Adverse effectmedia_commonOriginal ResearchPharmacologyAnakinraAnakinra Canakinumab Drug retention rate Interleukin 1-beta Systemic juvenile idiopathic arthritis Therapytherapybusiness.industrylcsh:RM1-950Hazard ratioInterleukinJuvenile idiopathic arthritisRetention ratemedicine.diseaseCanakinumablcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisSystemic juvenile idiopathic arthritidrug retention ratebusinessmedicine.druganakinraFrontiers in pharmacology
researchProduct